Eli Lilly and Company raises full-year guidance to $82-$85B revenue after Q1 earnings beat

Show summary Hide summary

• 🔥 Quick Facts
• Mounjaro and Zepbound Drive Dominant Market Position
• International Markets Show Explosive Long-Term Potential
• Financial Performance Metrics Exceed Wall Street Expectations
• Pipeline Strength and Strategic Acquisitions Position Future Growth
• What Does This Earnings Explosion Mean for Investors and Patient Access?
  • Sources

Eli Lilly and Company crushed earnings expectations with a blowout Q1 2026 report, posting 56% revenue growth as blockbuster obesity and diabetes drugs Zepbound and Mounjaro continued their remarkable surge. The pharmaceutical giant raised its full-year revenue guidance to $82-$85 billion, up $2 billion from prior expectations.

Mounjaro and Zepbound Drive Dominant Market Position

Mounjaro, Eli Lilly’s diabetes treatment, posted worldwide revenue of $8.66 billion in Q1, soaring 125% year-over-year. The surge was driven by 65% volume growth as demand exploded across markets. U.S. sales of Mounjaro reached $4.2 billion, while international revenue jumped to $4.4 billion from just $1.2 billion a year prior. China’s addition of Mounjaro to its National Reimbursed Drug List fueled international expansion.

Zepbound, the blockbuster obesity drug, generated $4.16 billion in U.S. revenue, up 80% year-over-year. Despite lower realized prices from competitive discounting, volume gains more than compensated. The company now holds 60.1% market share in the U.S. GLP-1 market, vastly outpacing rival Novo Nordisk at 39.4%.

International Markets Show Explosive Long-Term Potential

Revenue outside the U.S. jumped 81% to $7.7 billion in Q1, driven by a remarkable 95% surge in volume. CEO David Ricks emphasized that Eli Lilly is now in its third or fourth quarter of launches across major international markets after resolving supply constraints from late 2024. He noted strong organic consumer demand as patients pay out-of-pocket in Europe, China, and Brazil.

U.S. revenue climbed 43% to $12.1 billion, powered by 49% volume growth from Mounjaro and Zepbound prescriptions. Lower realized prices remained a headwind, particularly for Zepbound following publicly announced cash-pay reductions.

Financial Performance Metrics Exceed Wall Street Expectations

Metric	Q1 2026 Result	Expectation	Beat / Miss
Adjusted EPS	$8.55	$6.66	Beat by 28%
Revenue	$19.80B	$17.62B	Beat by 12.5%
Net Income	$7.40B	TBA	Up 168%
Gross Margin	81.9%	Prior 82.5%	Slight decline

“2026 is off to a strong start, we delivered 56% revenue growth in the first quarter and raised our full-year revenue guidance by $2 billion. A key milestone was the U.S. FDA approval of Foundayo, the only approved GLP-1 pill that can be taken any time of day, without food and water restrictions.”

— David A. Ricks, Lilly Chair and CEO

Pipeline Strength and Strategic Acquisitions Position Future Growth

Eli Lilly announced FDA approval of Foundayo, its oral GLP-1 pill, in April, launching in Q2 2026. CEO Ricks reported over 20,000 patients started Foundayo in its first few weeks, with more than 1,000 new patients daily. Notably, 80% of Foundayo users were new to GLP-1s, indicating market expansion rather than mere cannibalization. The company made four strategic acquisitions, including Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and Ajax Therapeutics, strengthening its pipeline across cell therapy and specialty care.

Phase 3 results showed Foundayo delivered superior diabetes control compared to oral semaglutide in head-to-head trials published in The Lancet. The company also reported positive psychotherapy outcomes for Taltz plus Zepbound combination therapy in adults with psoriatic arthritis and obesity.

What Does This Earnings Explosion Mean for Investors and Patient Access?

The $2 billion guidance raise reflects extraordinary confidence in GLP-1 market penetration over coming quarters. With Medicare obesity drug coverage expected later in 2026, Eli Lilly anticipates reaching millions of previously underserved patients. However, pricing pressure looms from government drug pricing negotiations and competitive discounting by Novo Nordisk. Ricks expects lower prices to accelerate prescription volumes globally, estimating GLP-1 use could rise from 20 million patients at year-end 2025 to 30 million by end of 2026. Will Eli Lilly’s dominance in GLP-1 applications extend to emerging markets as healthcare systems adopt these blockbuster treatments?

Sources

• Eli Lilly Investor Relations – Official Q1 2026 earnings release and financial results
• CNBC – Eli Lilly CEO David Ricks exclusive interview on earnings and Foundayo momentum
• Quartz – Q1 2026 earnings analysis covering Mounjaro and Zepbound sales trajectory